CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 25, 2019--
Sesen Bio (Nasdaq: SESN), a late-stage clinical company
developing targeted fusion protein therapeutics for the treatment of
people with cancer, today announced that Company management will host a
conference call and webcast on Monday, March 4, 2019 at 8:00 a.m. EST to
review operating results for the fourth quarter and full year ended
December 31, 2018 and new, preliminary analyses from the Phase 3 VISTA
trial of Vicinium®for patients with high-risk non-muscle
invasive bladder cancer who have been previously treated with bacillus
To participate in the conference call, please dial (844) 831-3025
(domestic) or (315) 625-6887 (international) and refer to conference ID
2179668. The webcast can be accessed in the Investor Relations section
of the Company's website at www.sesenbio.com.
The replay of the webcast will be available in the investor section of
the Company’s website at www.sesenbio.com
for 60 days following the call.
About Sesen Bio
Sesen Bio, Inc. is a late-stage clinical
company advancing targeted fusion protein therapeutics for the treatment
of patients with cancer. The Company’s lead program, Vicinium®, also
known as VB4-845, is currently in a Phase 3 registration trial, the
VISTA trial, for the treatment of high-risk, BCG un-responsive
non-muscle invasive bladder cancer. Updated twelve-month data from the
trial are anticipated in mid-2019. Vicinium incorporates a
tumor-targeting antibody fragment and a protein cytotoxic payload into a
single protein molecule designed to selectively and effectively kill
cancer cells, while minimizing toxicity to non-cancerous bladder cells.
For more information, please visit the Company’s website at www.sesenbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190225006040/en/
Source: Sesen Bio, Inc.
Erin Clark, Executive Director, Strategic Planning & Investor Relations